Viridian Therapeutics, Inc. (VRDN) Misses Q2 EPS by 2c

Viridian Therapeutics, Inc. (NASDAQ: VRDN) reported Q2 EPS of ($1.05), $0.02 worse than the analyst estimate of ($1.03). Revenue for the quarter came in at $280 thousand versus the consensus estimate of $28 thousand.

For earnings history and earnings-related data on Viridian Therapeutics, Inc. (VRDN) click here.

You May Also Be Interested In

• Barrick Mining said to delay IPO of American gold business to 2027
• Sell Recreational Cannabis as "Medicine"- Federal Class Action Alleges a "Concerted Campaign"
• Scorpio Gold says trading halt on its shares was made in error